Gene Therapy for Rare Diseases: Hope for the 300 Million

Introduction: The Invisible Majority

Three hundred million people. That is roughly the population of the United States, or more than the combined populations of Germany, France, Italy, and Spain. And yet, when it comes to medical research, drug development, and public awareness, these 300 million people are often invisible.

They are the global rare disease community — individuals living with one of an estimated 7,000 to 10,000 rare diseases, conditions so uncommon that each one may affect only a handful of families. In the United States, a disease is classified as "rare" if it affects fewer than 200,000 people. In Europe, the threshold is even lower: fewer than 1 in 2,000 individuals. By themselves, each condition is vanishingly small. Taken together, rare diseases represent one of the largest unmet medical needs in the world.

For decades, these patients waited in silence. There were no treatments. There was little research. Pharmaceutical companies looked at the tiny patient populations and concluded there was no viable market. Doctors often could not even provide a diagnosis, let alone a cure.

Then gene therapy arrived — and with it, a reason to hope.

What Makes a Disease "Rare" — and Why 80% Are Genetic

The defining characteristic of a rare disease is its low prevalence. But beyond the numbers, rare diseases share several features that make them uniquely challenging. The majority — roughly 80%, according to the National Institutes of Health — have a genetic origin. Many are monogenic, meaning they are caused by mutations in a single gene. Conditions like spinal muscular atrophy (SMA), sickle cell disease, hemophilia B, Duchenne muscular dystrophy, and Leber congenital amaurosis all trace their devastation to errors in one gene.

This genetic simplicity, paradoxically, is what makes rare diseases such promising targets for gene therapy. If a disease is caused by a single broken gene, fixing or replacing that gene offers a clear path to treatment — even a cure.

But simplicity in biology does not translate to simplicity in practice. Rare diseases disproportionately affect children. Approximately 50% of those affected are pediatric patients, and 30% of children with a rare disease will not live to see their fifth birthday. The urgency is immense, the stakes are life and death, and the clock is always ticking.

Many rare disease patients endure what is known as the "diagnostic odyssey" — years of visits to specialists, misdiagnoses, and uncertainty before finally receiving an answer. On average, it takes five to seven years to receive a rare disease diagnosis, and during that time, many patients deteriorate irreversibly. For conditions that cause progressive neurodegeneration, muscle wasting, or organ damage, every month without treatment matters.

Why Gene Therapy Is Uniquely Suited to Rare Diseases

Traditional drug development follows a pattern: identify a disease mechanism, design a molecule that modulates that mechanism, test it in large clinical trials, and bring it to market. This approach works well for common diseases with large patient populations. For rare diseases, it often fails — not because the science is impossible, but because the economics do not add up.

Gene therapy upends this equation. Instead of treating symptoms with chronic medications, gene therapy aims to address the root cause by delivering a functional copy of the defective gene, silencing a harmful gene, or directly editing the DNA. For monogenic rare diseases, this is not just a theoretical advantage. It is a fundamental shift in what medicine can accomplish.

Several features make gene therapy especially well-suited to rare diseases:

A clear genetic target. When a disease is caused by a single gene, there is no ambiguity about what needs to be fixed. This clarity accelerates research and simplifies the development pathway.

The potential for a one-time treatment. Many gene therapies are designed to be administered once, with the goal of providing lasting or even permanent benefit. For patients who would otherwise need lifelong treatment — or for whom no treatment exists at all — this is transformative.

Smaller clinical trials are often acceptable. Given the rarity of these conditions, regulators like the FDA have established pathways that allow for smaller, sometimes single-arm trials. This makes gene therapy development feasible even for diseases affecting only a few hundred patients.

Measurable biological endpoints. In many monogenic diseases, scientists can measure whether the therapy is working at the molecular level — for example, by checking whether a missing protein is now being produced. This clarity benefits both trial design and regulatory review.

These advantages have made rare diseases the proving ground for gene therapy. The first gene therapies to reach patients were developed for rare conditions, and rare diseases continue to dominate the gene therapy pipeline.

Approved Gene Therapies: A Growing List of Firsts

As of early 2026, a growing number of gene therapies have received regulatory approval for rare diseases. Each one represents years of research, clinical trials, and advocacy — and for the patients and families affected, each one represents the difference between hope and hopelessness.

Luxturna (Voretigene Neparvovec) — 2017

Luxturna was the first FDA-approved gene therapy for a genetic disease. It treats Leber congenital amaurosis type 2, a rare inherited retinal dystrophy caused by mutations in the RPE65 gene that leads to progressive vision loss and often blindness. Luxturna delivers a functional copy of the RPE65 gene directly to the retinal cells via an adeno-associated virus (AAV) vector. In clinical trials, patients who had been legally blind gained the ability to navigate obstacle courses in dim light — a result that brought researchers and families alike to tears. The treatment is administered as a one-time subretinal injection in each eye.

Zolgensma (Onasemnogene Abeparvovec) — 2019

Zolgensma treats spinal muscular atrophy (SMA) type 1, the leading genetic cause of infant death. SMA type 1 is caused by mutations in the SMN1 gene, which result in progressive loss of motor neurons. Without treatment, most children with SMA type 1 do not survive past age two and never achieve the ability to sit independently. Zolgensma delivers a functional SMN1 gene via an AAV9 vector in a single intravenous infusion. Children treated early — ideally before symptoms appear, through newborn screening — have achieved milestones that were previously unimaginable: sitting, standing, and in some cases, walking. At launch, Zolgensma carried a price tag of $2.1 million, making it the most expensive drug in the world at the time and igniting fierce debates about the cost of gene therapy.

Hemgenix (Etranacogene Dezaparvovec) — 2022

Hemgenix is a gene therapy for hemophilia B, a bleeding disorder caused by deficiency of clotting factor IX. Patients with hemophilia B require regular infusions of factor IX to prevent life-threatening bleeding episodes. Hemgenix uses an AAV5 vector to deliver a gene encoding a high-activity variant of factor IX to liver cells, enabling the body to produce its own clotting factor. In clinical trials, the majority of patients no longer needed routine factor IX prophylaxis after a single infusion. Priced at $3.5 million, Hemgenix surpassed Zolgensma as the most expensive therapy ever approved — though its developers argued the cost was justified by the lifetime savings on factor IX replacement therapy.

Casgevy (Exagamglogene Autotemcel) — 2023

Casgevy made history as the first CRISPR-based gene therapy to receive regulatory approval anywhere in the world. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, it treats sickle cell disease and transfusion-dependent beta-thalassemia — two of the most common monogenic disorders globally. Rather than adding a new gene, Casgevy uses CRISPR-Cas9 to edit the patient's own bone marrow stem cells, reactivating the production of fetal hemoglobin to compensate for the defective adult hemoglobin. The treatment requires myeloablative conditioning (chemotherapy to clear the existing bone marrow) followed by infusion of the edited cells. In trials, the vast majority of sickle cell patients were free of vaso-occlusive crises, and beta-thalassemia patients achieved transfusion independence. Casgevy represented the moment when gene editing moved from laboratory promise to clinical reality.

Skysona (Elivaldogene Autotemcel) — 2022

Skysona treats cerebral adrenoleukodystrophy (CALD), a devastating neurological condition in young boys caused by mutations in the ABCD1 gene. CALD leads to progressive destruction of the myelin sheath in the brain, resulting in loss of neurological function and death, typically within a few years of symptom onset. Skysona uses a lentiviral vector to deliver a functional ABCD1 gene to the patient's own stem cells, which are then transplanted back after chemotherapy conditioning. While not a cure — treated boys still carry the underlying mutation in most of their cells — the therapy has slowed or stabilized neurological deterioration in many patients, offering precious additional years of functional life.

Lenmeldy (Atidarsagene Autotemcel) — 2024

Lenmeldy received FDA approval for the treatment of metachromatic leukodystrophy (MLD), a lysosomal storage disorder that progressively destroys the nervous system. Caused by mutations in the ARSA gene, MLD typically manifests in early childhood and leads to loss of motor and cognitive function, with most affected children dying within a few years of symptom onset. Lenmeldy delivers a functional ARSA gene to the patient's own hematopoietic stem cells using a lentiviral vector. When treated before symptoms appear or very early in the disease course, children have shown dramatic preservation of neurological function compared to the natural history of the disease. Priced at $4.25 million, Lenmeldy became the most expensive drug in the world — a distinction that reflects both the extraordinary complexity of its manufacture and the life-altering nature of its benefit.

The Orphan Drug Pathway and RMAT Designation

None of these therapies would exist without regulatory frameworks specifically designed to incentivize rare disease drug development. In the United States, the Orphan Drug Act of 1983 was a landmark piece of legislation that transformed the landscape. Before the Act, fewer than 40 drugs had been approved for rare diseases. The Act offered pharmaceutical companies a package of incentives: seven years of market exclusivity, tax credits for clinical research costs, waived FDA application fees, and access to grants for clinical research.

The impact was dramatic. Since 1983, the FDA has approved more than 600 orphan drugs, and thousands more are in development. For gene therapy specifically, orphan drug designation has been essential, providing the financial and regulatory breathing room needed to pursue treatments for conditions with tiny patient populations.

In 2016, the FDA introduced the Regenerative Medicine Advanced Therapy (RMAT) designation, which provides additional support for regenerative medicine products — including gene therapies — that address serious conditions. RMAT designation offers all the benefits of breakthrough therapy designation plus additional opportunities for early and frequent FDA interactions, potential for accelerated approval based on surrogate or intermediate endpoints, and priority review. For gene therapy developers working on rare diseases, RMAT designation has become an important accelerator.

These regulatory pathways acknowledge a fundamental reality: the traditional drug development model was not built for rare diseases, and without deliberate policy intervention, the 300 million would remain untreated.

N-of-1 Therapies: Personalized Medicine at Its Most Extreme

Even among rare diseases, some conditions are so uncommon that they affect only a single patient — or are caused by unique, private mutations that require a bespoke therapeutic approach. This has given rise to the concept of "N-of-1" gene therapies: treatments designed and manufactured for a single individual.

The most famous example is the story of Mila Makovec, a young girl with Batten disease caused by a unique mutation in the CLN7 gene. Researchers at Boston Children's Hospital, led by Dr. Timothy Yu, developed an antisense oligonucleotide (ASO) tailored specifically to Mila's mutation in less than a year — an extraordinary feat of rapid science. The treatment, called milasen, was administered under FDA's compassionate use framework. While Mila's condition had already progressed significantly and she sadly passed away in 2021, her case demonstrated that personalized genetic medicines could be developed on an unprecedented timeline.

Since then, several academic and nonprofit programs have emerged to advance N-of-1 therapies. The n-Lorem Foundation, founded by Dr. Stanley Crooke (the pioneer of antisense technology), provides free personalized ASO therapies to patients with ultra-rare conditions on a lifetime basis. By early 2026, n-Lorem has treated dozens of patients with unique or near-unique genetic conditions that would never attract commercial drug development.

The challenge with N-of-1 therapies is not scientific feasibility — it is scalability and sustainability. Each treatment requires individual manufacturing, testing, and regulatory navigation. The FDA has been remarkably open to accommodating these therapies under expanded access and compassionate use frameworks, but the long-term model for funding and scaling such efforts remains an open question.

Patient Advocacy: The Engine That Drives Rare Disease Research

Behind every approved gene therapy for a rare disease, there is a community of patients, families, and advocates who refused to accept "nothing can be done" as an answer. Patient advocacy has been the single most important force in driving rare disease research forward.

The National Organization for Rare Disorders (NORD), founded in 1983 by a coalition of patient advocates who helped pass the Orphan Drug Act, serves as the umbrella organization for the rare disease community in the United States. NORD provides patient assistance programs, funds research grants, and advocates for policies that support rare disease drug development.

But the real engine of rare disease research is often the disease-specific foundations — organizations created by parents and families who decided to fight for their children's lives. The Cystic Fibrosis Foundation's venture philanthropy model, which invested in the development of ivacaftor and subsequent CFTR modulators, has become the gold standard for patient-funded drug development. The foundation invested over $150 million in Vertex Pharmaceuticals and helped bring transformative therapies to roughly 90% of cystic fibrosis patients.

For gene therapy specifically, organizations like CureSMA, the Sickle Cell Disease Association of America, Parent Project Muscular Dystrophy, the MLD Foundation, and dozens of others have played critical roles in funding early research, building patient registries, advocating for newborn screening, supporting clinical trial recruitment, and ensuring that the patient voice is centered in the development process.

These advocacy organizations also perform a less visible but equally important function: building community. For families dealing with an ultra-rare condition, the isolation can be as devastating as the disease itself. Connecting with other families, sharing information, and knowing that someone else understands — these are lifelines that no drug can provide.

Clinical Trial Challenges: Small Populations, Big Questions

Conducting clinical trials for rare disease gene therapies is unlike any other area of drug development. The challenges are profound, and they require creative solutions.

Small patient populations. For many rare diseases, the total number of patients who could participate in a trial globally may be in the dozens or low hundreds. Traditional randomized, double-blind, placebo-controlled trials are often neither feasible nor ethical. Can you ask a parent to enroll their rapidly deteriorating child in a trial knowing there is a 50% chance they will receive a placebo? In most rare disease gene therapy trials, the answer is no.

Instead, rare disease trials often use natural history data as a comparator — comparing treated patients to the documented progression of untreated patients. This approach has its limitations. Natural history data may be incomplete, variable, or collected under different conditions. But it reflects a pragmatic compromise between scientific rigor and ethical imperative.

Heterogeneity of disease. Even within a single rare disease, there can be enormous variation in severity, age of onset, and rate of progression. This variability makes it harder to demonstrate treatment effects in small trials and requires careful patient selection and stratification.

Geographic dispersion. Rare disease patients are scattered around the world. Recruiting enough patients often requires international, multi-site trials, with all the logistical, regulatory, and cultural complexity that entails. A family in rural India with a child affected by a rare metabolic disorder faces a very different reality than a family in Boston.

Pediatric populations. Since many rare diseases manifest in childhood, clinical trials often involve pediatric patients. This adds layers of ethical oversight, requires age-appropriate endpoint measures, and demands particular sensitivity in informed consent processes.

Long-term follow-up. Gene therapies are intended to provide lasting benefit, but demonstrating durability requires years of follow-up — a challenge when the therapy has only recently been administered and the patient population is small. Regulators have increasingly accepted shorter-term surrogate endpoints for initial approval while requiring ongoing long-term studies.

Despite these challenges, the rare disease gene therapy field has demonstrated remarkable ingenuity. Adaptive trial designs, patient-reported outcomes, biomarker-driven endpoints, and real-world evidence collection are all being used to generate the evidence needed for approval.

The Commercial Sustainability Crisis

If the science of rare disease gene therapy has been a story of triumph, the business model has been a story of crisis.

The case of bluebird bio illustrates the challenge in stark terms. The company developed Skysona for cerebral adrenoleukodystrophy and Zynteglo for beta-thalassemia — two genuinely innovative gene therapies. Both received regulatory approval. Both demonstrated meaningful clinical benefit. And yet bluebird bio nearly collapsed.

The problem was multifaceted. Manufacturing gene therapies — especially those involving ex vivo modification of patient cells — is extraordinarily complex and expensive. Each treatment is essentially made-to-order, involving the collection of a patient's cells, genetic modification in a specialized facility, quality control testing, and shipment back to the treatment center. The costs are measured in hundreds of thousands of dollars per batch, and the manufacturing failures and delays can be devastating for both patients and companies.

On the reimbursement side, the picture was equally challenging. A one-time gene therapy priced at several million dollars clashes with a healthcare payment system designed for chronic, recurring treatments. Insurance companies and health systems are accustomed to spreading drug costs over time. A single, massive upfront payment — even if it represents better value over a patient's lifetime — creates cash flow challenges that the system was not built to handle.

Bluebird bio ultimately withdrew Zynteglo from the European market in 2021 after failing to reach satisfactory reimbursement agreements with European health authorities. In the US, the company pursued outcomes-based agreements and installment payment models, but the financial strain continued. By early 2024, the company had been acquired by a larger pharmaceutical entity.

The bluebird bio experience sent shockwaves through the gene therapy industry and raised a fundamental question: if the companies that develop gene therapies for rare diseases cannot sustain themselves commercially, who will continue to invest in this research?

Several solutions are being explored. Outcomes-based reimbursement models, where payment is tied to whether the therapy works, are gaining traction. The concept of "annuity-like" payment structures, where the cost is spread over several years, is being piloted. CMS (the Centers for Medicare and Medicaid Services) has introduced cell and gene therapy access models to help manage costs for state Medicaid programs. But no single solution has yet proven sufficient to resolve the fundamental tension between the cost of innovation and the ability to pay.

Disease-Agnostic Platforms: The Promise of Scalability

One of the most exciting developments in the gene therapy field is the emergence of disease-agnostic platform technologies — approaches that can be rapidly adapted to treat multiple conditions without starting from scratch each time.

The concept is straightforward: rather than developing a unique manufacturing process, vector design, and regulatory package for every disease, create a modular platform where the only thing that changes between diseases is the therapeutic gene payload. The delivery system, manufacturing process, quality controls, and much of the regulatory framework remain constant.

AAV-based platforms have been the most advanced in this regard. Companies and academic groups have developed standardized AAV manufacturing processes that can produce vectors carrying different therapeutic genes for different diseases. This reduces the time and cost of development for each subsequent indication.

CRISPR-based approaches are also moving toward platform status. The ability to reprogram the guide RNA to target different genes while keeping the rest of the system constant is inherently modular. Base editing and prime editing further expand the toolkit, offering precise single-nucleotide changes without the double-strand breaks associated with traditional CRISPR-Cas9.

Lipid nanoparticle (LNP) delivery of mRNA — the technology behind the COVID-19 vaccines — is being explored as another disease-agnostic platform for genetic medicines. By encapsulating different mRNA payloads in the same LNP formulation, researchers can potentially address multiple diseases using a single delivery system. While mRNA-based approaches do not provide permanent genetic correction (the mRNA is eventually degraded), they offer the advantage of redosability and a well-characterized safety profile.

These platform approaches hold the potential to dramatically reduce the cost and timeline of gene therapy development, making it feasible to pursue treatments for diseases that affect only a few dozen or a few hundred patients worldwide.

Global Access Inequity: The Harshest Reality

For all the scientific progress, the benefits of gene therapy remain profoundly unevenly distributed. The approved gene therapies discussed in this article are available primarily in the United States, parts of Western Europe, and a handful of other high-income countries. For the vast majority of the 300 million people living with rare diseases worldwide — particularly those in low- and middle-income countries — these treatments might as well not exist.

The barriers are numerous and reinforcing. Gene therapies require specialized treatment centers with expertise in cell processing, genetic testing, and post-treatment monitoring. They require cold chain logistics that may not exist in rural or under-resourced settings. They require healthcare systems that can absorb costs of millions of dollars per patient. And they require the diagnostic infrastructure to identify patients in the first place — something that is sorely lacking in much of the world.

Sickle cell disease is perhaps the most painful example of this inequity. It is overwhelmingly a disease of sub-Saharan Africa, where approximately 75% of the 300,000 babies born each year with sickle cell disease are born. Casgevy and Lyfgenia (another gene therapy for sickle cell disease) are approved in the US and UK. But in Nigeria, the Democratic Republic of Congo, Tanzania, and other high-burden countries, these therapies are entirely inaccessible. The children who bear the greatest burden of this disease are the last in line for the treatments that could save their lives.

Global efforts to address this inequity are underway but remain insufficient. The Bill and Melinda Gates Foundation has invested in developing lower-cost gene therapies for sickle cell disease that could be deployed in Africa. The WHO has begun to engage with gene therapy as a global health priority. Academic groups are exploring in vivo gene therapy approaches — where the genetic medicine is delivered directly to the patient without the need for ex vivo cell processing — as a way to simplify treatment and reduce costs.

But the gap between what is scientifically possible and what is actually accessible remains vast. Closing that gap will require not just scientific innovation but sustained political will, creative financing, and a commitment to the principle that a child's chance of survival should not depend on the country in which they were born.

The Future: Reason for Cautious Optimism

Despite the challenges — commercial sustainability, global access, manufacturing complexity, and the sheer number of diseases still without treatment — there are strong reasons for optimism about the future of gene therapy for rare diseases.

The gene therapy pipeline is robust and growing. As of 2026, hundreds of gene therapy clinical trials are underway for rare diseases, spanning nearly every therapeutic area: hematology, neurology, ophthalmology, metabolic diseases, immunology, and more. New delivery technologies — including engineered AAV capsids, non-viral delivery systems, and in vivo gene editing — are expanding the range of diseases that can be addressed.

Regulatory agencies are becoming more experienced and more flexible. The FDA's Peter Marks, who leads the Center for Biologics Evaluation and Research, has been a vocal champion of gene therapy innovation and has committed to streamlining the approval pathway. In January 2025, the FDA released updated guidance on expedited programs for regenerative medicine therapies, further reducing barriers to development.

Newborn screening programs are expanding to include more genetic conditions, enabling earlier identification of patients who could benefit from gene therapy — often before irreversible damage has occurred. This shift from treatment to prevention represents the ultimate promise of genetic medicine.

Perhaps most importantly, the rare disease community itself remains relentless. Families continue to organize, fundraise, advocate, and participate in research. They are the reason the field exists, and they are the reason it will continue to advance.

The 300 million are no longer invisible. They are patients with names, families with stories, and communities with power. Gene therapy has given them something they were told they could never have: a reason to hope. The challenge now is to ensure that this hope reaches not just the few who can access these treatments today, but every patient, everywhere, who needs them.

---

Sources

1. National Institutes of Health (NIH). "FAQs About Rare Diseases." National Center for Advancing Translational Sciences. https://rarediseases.info.nih.gov/

2. Global Genes. "RARE Facts." https://globalgenes.org/rare-disease-facts/

3. U.S. Food and Drug Administration. "Orphan Drug Act — Relevant Excerpts." https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products

4. U.S. Food and Drug Administration. "Approved Cellular and Gene Therapy Products." https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

5. Russell, S., et al. "Efficacy and Safety of Voretigene Neparvovec (AAV2-hRPE65v2) in Patients with RPE65-Mediated Inherited Retinal Dystrophy." The Lancet 390, no. 10097 (2017): 849–860.

6. Mendell, J.R., et al. "Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy." New England Journal of Medicine 377, no. 18 (2017): 1713–1722.

7. Pipe, S.W., et al. "Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B." New England Journal of Medicine 388, no. 8 (2023): 706–718.

8. Frangoul, H., et al. "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Beta-Thalassemia." New England Journal of Medicine 384, no. 3 (2021): 252–260.

9. Kim, J., et al. "Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease." New England Journal of Medicine 381, no. 17 (2019): 1644–1652.

10. National Organization for Rare Disorders (NORD). "About NORD." https://rarediseases.org/

11. n-Lorem Foundation. "Our Mission." https://www.nlorem.org/

12. Piel, F.B., et al. "Global Burden of Sickle Cell Anaemia in Children under Five." The Lancet 381, no. 9861 (2013): 142–151.

13. U.S. Food and Drug Administration. "Regenerative Medicine Advanced Therapy Designation." https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation

14. Alliance for Regenerative Medicine. "2025 Annual Report: State of the Industry." https://alliancerm.org/

15. Cystic Fibrosis Foundation. "Venture Philanthropy Model." https://www.cff.org/